Skip to main content
SpringerLink
Log in

The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Antiphospholipid syndrome (APS) is an autoimmune disease that is characterized by the presence of thromboses and/or recurrent pregnancy losses (RPL). The persistent presence of antiphospholipid antibodies (aPL Abs): IgG and/or IgM isotypes of the anticardiolipin and/or anti-β2 glycoprotein I antibodies and lupus anticoagulant is mandatory for the laboratory diagnosis of APS. Due to the heating debate on the relevance of the IgM isotype of aPL Abs as a laboratory criterion defining APS, the focus of this article was to analyze whether both the IgG and IgM isotype of anti-annexin A5 Abs have equal relevance for clinical and serological features of patients with primary APS (PAPS). The IgG isotype of anti-annexin A5 Abs is associated with RPL in PAPS patients, although it is not elucidated whether these Abs are the cause or the consequence of RPL in PAPS. No data that could substantiate the association of the IgG and/or the IgM isotypes of anti-annexin A5 Abs with the presence of arterial and/or venous thromboses and/or their main complications in PAPS is available so far. However, the presence of clinical manifestations of the PAPS is increasing with the multiple positivity for aPL Abs and the IgM isotype of anti-annexin A5 Abs. The importance of the IgM isotype of anti-annexin A5 Abs in PAPS needs further elucidation due to the facts that majority of the available articles did not differentiate between both isotypes or only investigated the IgG isotype of anti-annexin A5 Abs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. van den Hoogen LL, van Roon JAG, Radstake TRDJ, Fritsch-Stork RDE, Derksen RHWM (2015) Delineating the deranged immune system in the antiphospholipid syndrome. Autoimmun Rev. doi:10.1016/j.autrev.2015.08.011

    PubMed  Google Scholar 

  2. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R et al (2014) 14th International congress on antiphospholipid antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13:917–930

    Article  PubMed  Google Scholar 

  3. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 4:295–306

    Article  CAS  PubMed  Google Scholar 

  4. Lee KO, Kim WJ, Na SJ, Heo JH, Lee KY (2011) Clinical significance of anti-annexin V antibody in acute cerebral ischemia. J Neurol Sci 305:53–56

    Article  CAS  PubMed  Google Scholar 

  5. Bećarević M, Lj Stojanovich, Ignjatović S, Dopsaj V (2016) The IgM isotype of anti-annexin a5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome. Clin Rheumatol 35:1361–1365

    Article  PubMed  Google Scholar 

  6. http://www24.brinkster.com/annexins/

  7. Gerke V, Moss SE (2002) Annexins: from structure to function. Physiol Rev 82:331–371

    Article  CAS  PubMed  Google Scholar 

  8. Peng B, Guo C, Guan H, Liu S, Sun MZ (2014) Annexin A5 as a potential marker in tumors. Clin Chim Acta 427:42–48

    Article  CAS  PubMed  Google Scholar 

  9. Laohavisit A, Davies JM (2009) Multifunctional annexins. Plant Sci 177:532–539

    Article  CAS  Google Scholar 

  10. Hayes MJ, Longbottom RE, Moss SE (2007) Annexinopathies. In: Carafoli E, Brini M (eds) Calcium signaling and disease. Springer, New York, pp 1–28

    Chapter  Google Scholar 

  11. Rescher U, Gerke V (2004) Annexins—unique membrane binding proteins with diverse functions. J Cell Sci 117:2631–2639

    Article  CAS  PubMed  Google Scholar 

  12. Bouter A, Carmeille R, Gounou C, Bouvet F, Degrelle SA, Evain-Brion D et al (2015) Annexin A5 and cell membrane repair. Placenta. doi:10.1016/j.placenta.2015.01.193

    PubMed  Google Scholar 

  13. Trouvé P, Le Drévo MA, Kerbiriou M, Friocourt G, Fichou Y, Gillet D et al (2007) Annexin V is directly involved in cystic fibrosis transmembrane conductance regulator’s chloride channel function. Biochim Biophys Acta 1772:1121–1133

    Article  PubMed  Google Scholar 

  14. van Tits LJH, van Heerde WL, van der Vleuten GM, de Graaf J, Grobbee DE, van de Vijver LPL et al (2007) Plasma annexin A5 level relates inversely to the severity of coronary stenosis. Biochem Biophys Res Comm 356:674–680

    Article  PubMed  Google Scholar 

  15. Rand JH, Wu XX, Quinn AS, Taatjes DJ (2010) The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus 19:460–469

    Article  CAS  PubMed  Google Scholar 

  16. Iaccarino L, Ghirardello A, Canova M, Zen M, Bettio S, Nalotto L et al (2011) Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. Autoimmun Rev 10:553–558

    Article  CAS  PubMed  Google Scholar 

  17. Cederholm A, Svenungsson E, Jensen-Urstad K, Trollmo C, Ulfgren AK, Swedenborg J, Fei GZ, Frostegard J (2005) Decreased binding of annexin V to endothelial cells: a potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arterioscler Thromb Vasc Biol 25:198–203

    CAS  PubMed  Google Scholar 

  18. Cederholm A, Johan Frostegard J (2005) Annexin A5 in cardiovascular disease and systemic lupus erythematosus. Immunobiology 210:761–768

    Article  CAS  PubMed  Google Scholar 

  19. Cederholm A, Frostegård J (2007) Annexin A5 as a novel player in prevention of atherothrombosis in SLE and in the general population. Ann NY Acad Sci 1108:96–103

    Article  CAS  PubMed  Google Scholar 

  20. Bećarević M, Singh S, Majkić-Singh N (2008) Oxidized LDL, anti-oxidized LDL and anti-annexin A5 antibodies in primary antiphospholipid syndrome. Clin Lab 54:97–101

    PubMed  Google Scholar 

  21. Domeij H, Hua X, Su J, Bäcklund A, Yan Z, Frostegård AG et al (2013) Annexin A5 inhibits atherogenic and pro-inflammatory effects oflysophosphatidylcholine. Prostag Other Lipid Mediat 106:72–78

    Article  CAS  Google Scholar 

  22. Camors E, Monceau V, le Charlemagne D (2005) Annexins and Ca2+ handling in the heart. Cardiovasc Res 65:793–802

    Article  CAS  PubMed  Google Scholar 

  23. Markoff A, Gerke V (2005) Expression and functions of annexins in the kidney. Am J Physiol Ren Physiol 289:949–956

    Article  Google Scholar 

  24. van Heerde L, Lap P, Schoormans S, de Groot PG, Reutelingsperger C, Vroom T (2004) Localization of annexin A5 in human tissues. Annexins 1:e56–e62

    Google Scholar 

  25. Shu F, Sugimura M, Kanayama N, Kobayashi H, Kobayashi T, Terao T (2000) Immunohistochemical study of annexin V expression in placentae of preeclamsia. Gynecol Obstet Investig 49:17–23

    Article  CAS  Google Scholar 

  26. Ulander VM, Stefanovic V, Masuda J, Suzuki K, Hiilesmaa V, Kaaja R (2007) Plasma levels of annexins IV and V in relation to antiphospholipid antibody status in women with a history of recurrent miscarriage. Thromb Res 120:865–870

    Article  CAS  PubMed  Google Scholar 

  27. Esposito G, Tamby MC, Chanseaud Y, Servettaz A, Guillevin L, Mouthon L (2005) Anti-annexin V antibodies: are they prothrombotic? Autoimmun Rev 4:55–60

    Article  CAS  PubMed  Google Scholar 

  28. Gris JC, Quéré I, Sanmarco M, Boutiere B, Mercier E, Amiral J, Hubert AM et al (2008) Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss The nîmes obstetricians and haematologists study-NOHA. Thromb Haemost 84:228–236

    Google Scholar 

  29. Zammiti W, Mtiraoui N, Hidar S, FekihM AlmawiWY, Mahjoub T (2006) Antibodies to β2- glycoprotein I and annexin V in women with early and late idiopathic recurrent spontaneous abortions. Arch Gynecol Obstet 274:261–265

    Article  CAS  PubMed  Google Scholar 

  30. Rezk A, Abdel-Hafeez N, Rageh IM, Abdalla W (2010) Anti-annexin as a marker in patients with recurrent miscarriages. Middle East Fertil Soc J 15:47–50

    Article  Google Scholar 

  31. Irman S, Skarabot M, Musevc I, Rozman B, Bozic B (2011) The use of atomic force microscopy to study the pathologic effects of anti-annexin autoantibodies. J Autoimmun 36:98–105

    Article  CAS  PubMed  Google Scholar 

  32. Bizzaro N, Tonutti E, Villalta D, Tampoia M, Tozzoli R (2005) Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages. Arch Pathol Lab Med 129:61–68

    PubMed  Google Scholar 

  33. Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T et al (2001) Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 47:1008–1015

    CAS  PubMed  Google Scholar 

  34. Arnold J, Holmes Z, Pickering W, Farmer C, Regan L, Cohen H (2001) Anti-beta2glicoprotein I and of anti-annexin V antibodies in women with recurrent miscarriages. Br J Haematol 113:911–914

    Article  CAS  PubMed  Google Scholar 

  35. De Laat B, Derksen RHWM, Mackie IJ et al (2006) Annexin A5 polimorphism (−1C > T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis 65(11):1468–1472

    Article  PubMed  PubMed Central  Google Scholar 

  36. Roldán V, Marín F, Pineda J, Marco P, Corral J, Climent V et al (2002) Annexin V levels in survivors of early myocardial infarction. Rev Esp Cardiol 55:1230–1234

    Article  PubMed  Google Scholar 

  37. Nayfe R, Uthman I, Aoun J, Aldin ES, Merashil M, Khamashta MA (2013) Seronegative antiphospholipid syndrome. Rheumatology 52:1358–1367

    Article  PubMed  Google Scholar 

  38. Gaspersic N, Rot U, Cucnik S, Bozic B, Kveder T, Rozman B (2003) Low prevalence of antiphospholipid antibodies in a series of young patients with cerebrovascular disease. Clin Exp Rheumatol 21:680

    CAS  PubMed  Google Scholar 

  39. Bećarević M, Ignjatović S, Majkić-Singh N (2012) Deterioration of thromboses in primary antiphospholipid syndrome: TNF-alpha and anti-annexin A5 antibodies. Clin Lab 58:1079–1084

    PubMed  Google Scholar 

  40. Rand JH, Wu XX (2004) Antibody-mediated interference with annexins in the antiphospholipid syndrome. Thromb Res 114:383–389

    Article  CAS  PubMed  Google Scholar 

  41. Del Ross T, Ruffatti A, Cuffaro S, Tonello M, Calliagaro A, Favaro M et al (2015) The clinical relevance of the IgM isotype of antiphospholipid antibodies in the vascular antiphospholipid syndrome. Thromb Res. doi:10.1016/j.thromres.2015.08.019

    PubMed  Google Scholar 

  42. Galli M, Luciani D, Bertolini G, Barbui T (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101(5):1827–1832

    Article  CAS  PubMed  Google Scholar 

  43. Forastiero R, Martinuzzo M, Pombo G, Puente D, Rossi A, Celebrin L et al (2005) A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and a risk of thrombosis. J Thromb Haemost 3(6):1231–1238

    Article  CAS  PubMed  Google Scholar 

  44. Forastiero R (2014) Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus 23(12):1252–1254

    Article  CAS  PubMed  Google Scholar 

  45. Pengo V (2011) Antiphospholipid syndrome: interpretation of laboratory data. J Thromb Haemost 9(2):402–403

    Article  CAS  PubMed  Google Scholar 

Download references

Author contribution

Mirjana Bećarević alone is responsible for the content and writing of the paper.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Medical Faculty, University of Novi Sad, Hajduk Veljkova 3, 21000, Novi Sad, Serbia

    Mirjana Bećarević

Authors
  1. Mirjana Bećarević
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mirjana Bećarević.

Ethics declarations

Conflict of interest

The author has no potential financial conflict of interest related to this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bećarević, M. The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome. J Thromb Thrombolysis 42, 552–557 (2016). https://doi.org/10.1007/s11239-016-1389-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-016-1389-5

Keywords

Search

Navigation